Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1.

被引：0
作者：
Hamai, Kosuke
Masuda, Takeshi
Fujitaka, Kazunori
Suzuki, Tomoko
Matsumoto, Naoko
Matsumura, Mirai
Isoyama, Shoko
Ueno, Sayaka
Mito, Mineyo
Yamaguchi, Kakuhiro
Sakamoto, Shinjiro
Kawano, Reo
Masuda, Ken
Nishino, Ryohei
Ishikawa, Nobuhisa
Yamasaki, Masahiro
Hattori, Noboru
机构：
[1] Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Japan
[2] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan
[3] JA Onomichi Gen Hosp, Dept Resp Internal Med, Onomichi, Japan
[4] Hiroshima Red Cross Hosp & Atom Bomb Survivors Ho, Dept Resp Internal Med, Hiroshima, Japan
[5] Kure Med Ctr, Dept Resp Internal Med, Hiroshima, Japan
[6] Hiroshima Univ Hosp, Hiroshima, Japan
[7] Hiroshima City Hiroshima Citizens Hosp, Dept Resp Internal Med, Hiroshima, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21156
引用
收藏
页数：1
相关论文
共 50 条
[41]   A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer [J].
Wu, Kai ;
Fu, Yifan ;
Zeng, Daxiong ;
Chen, Tao ;
Wang, Changguo ;
Jiang, Junhong .
JOURNAL OF THORACIC DISEASE, 2022, 14 (03) :679-688
[42]   BIWEEKLY CARBOPLATIN AND PACLITAXEL AS FIRST-LINE THERAPY FOR ELDERLY ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS (PHASE II STUDY) [J].
Kota, I. ;
Soejima, K. ;
Naoki, K. ;
Yasuda, H. ;
Terai, H. ;
Daisuke, A. ;
Ohgino, K. ;
Yoda, S. ;
Ikemura, S. ;
Betsuyaku, T. .
ANNALS OF ONCOLOGY, 2012, 23 :422-422
[43]   Phase II study of biweekly carboplatin and paclitaxel as first-line treatment for elderly patients with advanced non-small cell lung cancer [J].
Terai, H. ;
Soejima, K. ;
Nakamura, M. ;
Naoki, K. ;
Yasuda, H. ;
Satomi, R. ;
Nakayama, S. ;
Yoda, S. ;
Ikemura, S. ;
Sato, T. ;
Asano, K. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[44]   Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: A retrospective study [J].
Yu, S. ;
Xiaoqi, Y. .
JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (03)
[45]   Comparison of camrelizumab, pembrolizumab, tislelizumab, and sintilimab as first-line treatment in patients with non-small cell lung cancer: a retrospective study [J].
Yan, Xiaoqi ;
Wang, Yizong ;
Wu, Fei ;
Zhou, Guoren ;
Shen, Jiannan ;
Yu, Shaorong .
JOURNAL OF THORACIC DISEASE, 2025, 17 (02) :859-871
[46]   Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer [J].
Imai, Hisao ;
Kishikawa, Takayuki ;
Minemura, Hiroyuki ;
Yamada, Yutaka ;
Ibe, Tatsuya ;
Yamaguchi, Ou ;
Mouri, Atsuto ;
Hamamoto, Yoichiro ;
Kanazawa, Kenya ;
Kasai, Takashi ;
Kaira, Kyoichi ;
Kaburagi, Takayuki ;
Minato, Koichi ;
Kobayashi, Kunihiko ;
Kagamu, Hiroshi .
CANCER MEDICINE, 2021, 10 (20) :6971-6984
[47]   High neutrophils-to-lymphocyte ratio (NLR) predicts poor survival of high-PD-L1-expressing metastatic non-small cell lung carcinoma patients undergoing first-line immunotherapy with pembrolizumab [J].
Romano, F. J. ;
Barbato, C. ;
Arundine, D. ;
Ambrosio, F. ;
Ronga, R. ;
Failla, G. ;
Moccia, L. ;
Corcione, N. ;
Guggino, G. ;
Raucci, A. ;
Romano, L. ;
Campione, S. ;
De Dominicis, G. ;
Santoriello, C. ;
Tinto, A. ;
Russo, C. ;
De Michele, F. ;
Russo, A. ;
Starace, A. ;
Riccardi, F. .
ANNALS OF ONCOLOGY, 2021, 32 :S1379-S1379
[48]   Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis [J].
Ikezawa, Yasuyuki ;
Morita, Ryo ;
Mizugaki, Hidenori ;
Tateishi, Kazunari ;
Yokoo, Keiki ;
Sumi, Toshiyuki ;
Kikuchi, Hajime ;
Kitamura, Yasuo ;
Nakamura, Atsushi ;
Kobayashi, Maki ;
Aso, Mari ;
Kimura, Nozomu ;
Yoshiike, Fumiaki ;
Megumi, Furuta ;
Tanaka, Hisashi ;
Sekikawa, Motoki ;
Hachiya, Tsutomu ;
Nakamura, Keiichi ;
Hommura, Fumihiro ;
Sukoh, Noriaki ;
Ito, Kenichiro ;
Kikuchi, Takashi ;
Agatsuma, Toshihiko ;
Yokouchi, Hiroshi .
CANCER MEDICINE, 2024, 13 (14)
[49]   Efficacy and safety of first-line erlotinib in elderly patients with advanced non-small cell lung cancer [J].
Merimsky, Ofer ;
Cheng, Chi-Kin ;
Au, Joseph Siu-Kie ;
Von Pawel, Joachim ;
Reck, Martin .
ONCOLOGY REPORTS, 2012, 28 (02) :721-727
[50]   Platinum doublets as first-line treatment for elderly patients with advanced non-small cell lung cancer [J].
Piacentini, Paolo ;
Greco, Filippo ;
Mercanti, Anna ;
Trolese, Anna Rita ;
Durante, Emilia ;
Moratello, Giacomo ;
Tognetto, Michele ;
Furini, Lara ;
Giuliani, Jacopo ;
Bonetti, Andrea .
TUMORI JOURNAL, 2013, 99 (06) :650-655
12345